Harnessing serotonergic and dopaminergic pathways for lymphoma therapy: Evidence and aspirations

Research output: Contribution to journalArticle

Colleges, School and Institutes

Abstract

Growing evidence supports the notion that pharmaceutical targeting of the 5-hydroxytryptamine (5-HT) and dopamine (DA) systems offers the potential to treat human immune system disorders. This review describes this emerging area of research, which has the benefit of being supported by a relatively detailed understanding of these monoamine systems within other tissues of the body. Furthermore, the availability of a number of pharmaceutical agents originally developed to manipulate central monoamine function, offer many suitable drug candidates to test their therapeutic potential in the immune pathology arena.

Details

Original languageEnglish
Pages (from-to)218-25
Number of pages8
JournalSeminars in Cancer Biology
Volume18
Publication statusPublished - 1 Jun 2008

Keywords

  • serotonin, dopamine, novel drug targets, lymphoma, drug reprofiling